Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product: | H5N1 Influenza Vaccine |
Active Ingredient: | Influenza Virus Type A haemagglutinin 30mcg |
Dosage Form: | Suspension for injection |
New Zealand Sponsor: | Seqirus (NZ) Limited |
Manufacturer: | Seqirus Pty Limited, Melbourne, Australia |
Note: This consent is given subject to the following condition:
|
|
Note: This renewed consent is valid for two years from 9 February 2022. |
Dated this 9th day of February 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).